The integration of investigative toxicology in the drug discovery process.
Integrating toxicology early in the drug discovery process adds value by providing the earliest possible identification of a compound's potential for toxicological and pathological effects relevant to intended clinical use. With this approach true 'lead' candidates, with a high probability of clinical success, are identified and advanced while reducing effort and resources expended on compounds without the requisite therapeutic index. Resources are focussed on the speed of getting a discovery 'lead' into early clinical development, defining the mechanisms of observed preclinical toxicity and their relevance to human use, and developing early safety data with in vitro test systems ahead of in vivo systems where possible, thus reducing animal use.
Drug Safety Assessment Department, Sterling Winthrop Pharmaceuticals Research Division, Collegeville, PA 19426-0900.
J H
JH
Dean
H M
HM
Olson
D000818:Animals; D002626:Chemistry, Pharmaceutical; D004353:Drug Evaluation, Preclinical; D009152:Mutagenicity Tests; D012106:Research; D014116:Toxicology